Clinical Trials

At Imugene, we are dedicated to advancing healthcare through innovative clinical trials. Our research focuses on developing new treatments for solid tumours and blood cancers.

We currently have multiple clinical trials underway. Additional details for these trials including trial site locations and eligibility criteria can be found at clinicaltrials.gov

Participation in Imugene clinical trials is always based on the patient’s own decision. As the sponsor of our clinical trials, Imugene cannot be directly involved in the recruitment process. For further information on how to participate in our clinical trials, please contact your treating physician.

Azer-Cel (azercabtagene zapreleucel)

Open Label, Phase 1/1b Study in Relapsed/Refractory Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia

NOW RECRUITING IN AUSTRALIA & USA

*(NHL) Relapsed/Refractory Non-Hodgkin Lymphoma, (B-All) Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

onCARlytics (CF33 + CD19)

OASIS: Open Label, Phase 1 Study of CF33-CD19 in combination with blinatumomab in Mixed Advanced Solid Tumours

NOW RECRUITING IN THE USA

VAXINIA (CF33 + hNIS)

MAST: Open Label, Adaptive Phase 1 Study in Mixed Advanced Solid Tumours

NOW RECRUITING IN AUSTRALIA & USA

 

Neo-POLEM

Investigator Sponsored Study: Open Label, Phase 2 Study in Operable MSI-High Colorectal Cancer (CRC)

RECRUITMENT OPENING SOON IN THE UK & AUS

PD1-Vaxx (PD-1)

IMPRINTER: Open Label, Phase 1 Study of PD1-Vaxx in Adults with Non-Small Cell Lung Cancer

HER-Vaxx (HER-2)

nextHERIZON: Open Label, Phase 2 Study of HER-Vaxx in combination with chemotherapy or pembrolizumab in metastatic gastric cancer after progression on trastuzumab

HERIZON: Open Label, Phase 1b/2 study of HER-Vaxx and Chemotherapy compared to Chemotherapy only in patients with HER-2 positive advanced Gastric Cancer.